Skip to main content
Fig. 1 | Molecular Medicine

Fig. 1

From: Improved Anti-tumor Activity and Safety of Interleukin-13 Receptor Targeted Cytotoxin by Systemic Continuous Administration in Head and Neck Cancer Xenograft Model

Fig. 1

Comparison of anti-tumor activity of IL-13 cytotoxin in KCCT873 tumor xenografted nude mice between IV and CI routes. Male mice bearing subcutaneous tumor were treated with 50 µg/kg/day (A), 75 µg/kg/day (B), or 200 µg/kg/day (C) of IL13-PE38QQR by either IV or continuous infusion (CI) from day 4–10 (7 days). Abbreviations: CR, complete response. Experiments were performed twice with similar results.

Back to article page

Molecular Medicine

ISSN: 1528-3658